HIV infection and host genetic mutation among injecting drug-users of northeastern states of India.
A community-based cross-sectional study was conducted among injecting drug-users (IDUs) of the northeastern states of India to understand the host genetic factors that confer resistance to HIV infection. The study aimed at assessing the existence and magnitude of genetic mutations of chemokine receptors, such as CCR2-64I, CCR-5 D-32, and SDF-1-3'A, that are known to confer resistance to HIV infection and progression of disease in some set-ups. In total, 711 IDUs from Manipur, Mizoram, Nagaland, and Meghalaya were sampled for the study. The selected participants were interviewed to study their sociodemography, risk behaviours, and risk perceptions after obtaining their verbal informed consent. The interview was followed by collection of about 5 mL of blood samples by an unlinked anonymous method for studying genetic mutation and HIV infection. All the blood samples were transported to and processed at the clinical medicine laboratory of the National Institute of Cholera & Enteric Diseases, Kolkata, India. The genetic mutations were detected by polymerase chain reaction (PCR) and the restriction fragment length polymorphism (RFLP) assay techniques. The study revealed that 328 (46.1%) IDUs were aged 20-29 years, 305 (42.9%) were aged 30-39 years, and only two (0.3%) were aged above 49 years. The rate of HIV seropositivity varied widely among the IDUs living in different northeastern states that ranged from 4.5% to 61%. There was not a single IDU with CCR5 homozygous mutation. Mutated genes of CCR2-64I and SDF-1-3'A were detected in the frequencies of 49% and 23% respectively in them. The rate of HIV seropositivity in IDUs having CCR2 mutant gene was 27% (n=94) and without mutation was 27% (n=98). Similarly, HIV seropositivity in IDUs with and without SDF1 mutation was 28% (n=46) and 27% (n=146) respectively. Both the differences were not statistically significant. A CCR5 homozygous mutation is known to be the most prominent marker that confers resistance against HIV infection. The absence of CCRS mutant gene in this population suggests that they do not have any additional protection against HIV infection. Analysis also revealed that, although mutation of CCR2 and SDF1 was present in this population, it did not confer any additional resistance against HIV. This indicates that the IDUs of northeastern India are not additionally protected against HIV infection through genetic mutation and are, therefore, vulnerable to acquire HIV infection due to high-risk behaviour and other related factors.
Sarkar
Kamalesh
K
Division of Epidemiology [HIV/AIDS], National Institute of Cholera & Enteric Diseases P-33 CIT Road, Scheme XM Kolkata 700 010, India. kamalesh.sarkar@gmail.com
Das
Santa Sabuj
SS
Pal
Reshmi
R
Bal
Baishali
B
Madhusudan
P
P
Chakraborti
Sekhar
S
D000328:Adult; D017677:Age Distribution; D054377:Chemokine CXCL12 / Q000235:genetics; D003430:Cross-Sectional Studies; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000453:epidemiology* / Q000235:genetics*; D006801:Humans; D007194:India / Q000453:epidemiology; D008297:Male; D009154:Mutation / Q000235:genetics*; D016485:Needle Sharing / Q000706:statistics & numerical data; D016017:Odds Ratio; D016133:Polymerase Chain Reaction / Q000379:methods; D012150:Polymorphism, Restriction Fragment Length / Q000235:genetics; D054390:Receptors, CCR2 / Q000235:genetics; D019707:Receptors, Chemokine / Q000235:genetics; D015819:Substance Abuse, Intravenous / Q000097:blood / Q000453:epidemiology*; D055815:Young Adult
C515334:CCR2 protein, human; D054377:Chemokine CXCL12; D054390:Receptors, CCR2; D019707:Receptors, Chemokine
Natl Med J India. 2001 Jul-Aug;14(4):209-11
11547526
Br Med Bull. 2001;58:7-18
11714621
J Commun Dis. 1999 Mar;31(1):23-8
10810582
J Med Virol. 1999 May;58(1):54-8
10223546
BMC Public Health. 2006 Oct 10;6:248
17029648
Science. 1996 Sep 27;273(5283):1856-62
8791590
Bull Narc. 1993;45(1):91-105
8305909
Vaccine. 2008 Jun 6;26(24):2966-80
18321617
Eur J Hum Genet. 2000 Dec;8(12):975-9
11175286
J Urban Health. 2006 Jan;83(1):5-17
16736351
J Acquir Immune Defic Syndr. 2001 Aug 15;27(5):472-81
11511825
AIDS. 2000 Jan 7;14(1):75-83
10714570
Arch Intern Med. 2001 May 28;161(10):1281-8
11371255
J Acquir Immune Defic Syndr. 2004 Apr 15;35(5):503-10
15021315
Harv AIDS Rev. 1998 Fall;:1
12294441
Science. 1998 Jan 16;279(5349):389-93
9430590
Science. 1997 Aug 15;277(5328):959-65
9252328
Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5199-204
11320252
Am J Hum Genet. 1999 Oct;65(4):1047-53
10486323
J Psychoactive Drugs. 2006 Sep;38(3):305-10
17165373
Int J STD AIDS. 2003 Nov;14(11):762-4
14624740
Indian J Public Health. 1997 Apr-Jun;41(2):49-51
9988977
Subst Use Misuse. 2006;41(3):341-52
16467010
Rev Invest Clin. 2004 Mar-Apr;56(2):134-42
15377067
Harm Reduct J. 2008 Aug 25;5:29
18724872
J Infect Dis. 2006 Jan 1;193(1):16-26
16323127
PLoS One. 2008 Jul 23;3(7):e2747
18648518
AIDS Care. 2009 Jan;21(1):31-41
19085218
AIDS Care. 2000 Aug;12(4):497-504
11091782